- Home
- APLM vs XTLB Comparison
APLM vs XTLB Comparison
Compare APLM & XTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- XTLB
- Stock Information
- Founded
- APLM 2016
- XTLB 1993
- Country
- APLM United States
- XTLB Israel
- Employees
- APLM N/A
- XTLB N/A
- Industry
- APLM Blank Checks
- XTLB Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- XTLB Health Care
- Exchange
- APLM Nasdaq
- XTLB Nasdaq
- Market Cap
- APLM 15.6M
- XTLB 12.8M
- IPO Year
- APLM N/A
- XTLB 2005
- Fundamental
- Price
- APLM $0.14
- XTLB $2.20
- Analyst Decision
- APLM Strong Buy
- XTLB
- Analyst Count
- APLM 2
- XTLB 0
- Target Price
- APLM $4.25
- XTLB N/A
- AVG Volume (30 Days)
- APLM 876.0K
- XTLB 6.0K
- Earning Date
- APLM 08-14-2024
- XTLB 11-20-2024
- Dividend Yield
- APLM N/A
- XTLB N/A
- EPS Growth
- APLM N/A
- XTLB N/A
- EPS
- APLM N/A
- XTLB N/A
- Revenue
- APLM $2,101,000.00
- XTLB N/A
- Revenue This Year
- APLM N/A
- XTLB N/A
- Revenue Next Year
- APLM N/A
- XTLB N/A
- P/E Ratio
- APLM N/A
- XTLB N/A
- Revenue Growth
- APLM 70.54
- XTLB N/A
- 52 Week Low
- APLM $0.11
- XTLB $0.75
- 52 Week High
- APLM $2.06
- XTLB $4.99
- Technical
- Relative Strength Index (RSI)
- APLM 48.96
- XTLB 34.54
- Support Level
- APLM $0.13
- XTLB $2.13
- Resistance Level
- APLM $0.17
- XTLB $2.56
- Average True Range (ATR)
- APLM 0.01
- XTLB 0.12
- MACD
- APLM -0.00
- XTLB -0.02
- Stochastic Oscillator
- APLM 34.48
- XTLB 17.02
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About XTLB XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.